WALLDORF, Germany, June 11, 2013 /PRNewswire/ -- SAP AG (NYSE: SAP) and Technical University Munich (TUM) today announced ProteomicsDB, a new offering based on the SAP HANA® platform that stores protein and peptide identifications from mass spectrometry-based experiments. The proteomic data assembled in the new offering resulted in the identification of proteins mapping to over 18,000 human genes. This represents 90 percent coverage of the human proteome. Data stored and analyzed within ProteomicsDB can be used in basic and biomedical research for discovering therapeutic targets and developing new drugs as well as enhanced diagnosis methods.
As personalized medicine is on the rise, the healthcare field is discovering the opportunities of big data analysis. The result of a joint project between the TUM Chair of Proteomics and Bioanalytics, SAP and the SAP Innovation Center, ProteomicsDB is a major step forward in human proteomics. It currently contains more than 11,000 datasets from human cancer cell lines, tissues and body fluids and enables real-time analysis of this highly dimensional data and creates instant value by allowing to test analytical hypothesis.
ProteomicsDB will be available free of charge. The database will be a valuable asset for researchers in the field of life sciences as well as for the pharmaceutical and biotechnology industry. Insights from analyzing the inherent datasets can be used in biomedical research and for example in developing new drugs that operate in a more targeted way without adversely influencing other cellular processes, helping to reduce side effects.
"The vast amounts of molecular data generated in biomedical research increasingly challenge the ability of scientists to see 'the forest for the trees," said Prof. Dr. Bernhard Kuster of TUM. "ProteomicsDB is a significant step ahead in our research aiming at a better understanding of human disease and more informed future treatments. The software helps us and others to store, integrate and analyze experimental data in real time, allowing us to study more complex biological systems at greater depth than previously possible."
For more information, visit the SAP Newsroom.
Technische Universitat Munchen (TUM) is one of Europe's leading universities. It has roughly 500 professors, 9,000 academic and non-academic staff, and 32,000 students. It focuses on the engineering sciences, natural sciences, life sciences, medicine, and economic sciences. After winning numerous awards, it was selected as an "Excellence University" in 2006 and 2012 by the Science Council (Wissenschaftsrat) and the German Research Foundation (DFG). In both international and national rankings, TUM is rated as one of Germany's top universities and is dedicated to the ideal of a top-level research-oriented entrepreneurial university. The university's global presence includes offices in Beijing (China), Brussels (Belgium), Cairo (Egypt), Mumbai (India) and Sao Paulo (Brazil). The German Institute of Science and Technology (GIST - TUM Asia), founded in 2002 in Singapore, is the first research campus of a German university abroad. www.tum.de
As market leader in enterprise application software, SAP (NYSE: SAP) helps companies of all sizes and industries run better. From back office to boardroom, warehouse to storefront, desktop to mobile device – SAP empowers people and organizations to work together more efficiently and use business insight more effectively to stay ahead of the competition. SAP applications and services enable more than 238,000 customers to operate profitably, adapt continuously, and grow sustainably. For more information, visit www.sap.com.
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2013 SAP AG. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP AG in Germany and other countries. Please see http://www.sap.com/corporate-en/legal/copyright/index.epx#trademark for additional trademark information and notices.
For customers interested in learning more about SAP products: Global Customer Center: +49 180 534-34-24 United States Only: 1 (800) 872-1SAP (1-800-872-1727)
For more information, press only: Cathrin von Osten, +49 (6227) 7-63908, email@example.com, CET Samantha Finnegan, +1 (650) 276-9350, firstname.lastname@example.org, PDT SAP Press Office, +49 (6227) 7-46315, CET; +1 (610) 661-3200, EDT; email@example.com Barbara Wankerl, +49 (89) 289-22562, firstname.lastname@example.org, CET TUM Corporate Communications Center, +49 (89) 289-22778, CET, email@example.com
SOURCE SAP AG